Table 3.
Results of univariate analyses.
| Overall Mortality | DWFG | CVD Mortality | MACE | Graft Loss | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | p | HR | p | HR | p | HR | p | HR | p | |
| Age | 1.06 (1.03–1.09) | <0.001 | 1.10 (1.04–1.17) | <0.01 | 1.06 (1.01–1.10) | <0.05 | 1.03 (0.99–1.06) | 0.11 | ||
| Sex | 9.14 (1.21–68.94) | <0.01 | ||||||||
| Dialysis vintage | 1.01 (1.00–1.03) | 0.08 | 1.01 (1.00–1.02) | 0.10 | ||||||
| HLA MM I | 1.65 (1.10–2.48) | <0.05 | ||||||||
| HLA MM II | 1.68 (1.02–2.76) | <0.05 | ||||||||
| DGF | 1.87 (1.05–3.33) | <0.05 | 2.12 (0.79–5.75) | 0.14 | ||||||
| Smoking | 1.60 (0.82–3.13) | 0.17 | 1.91 (1.06–3.43) | <0.05 | ||||||
| CRP | 1.04 (1.00–1.09) | 0.08 | 1.04 (0.99–1.09) | 0.14 | ||||||
| Scr | 1.01 (1.01–1.01) | <0.001 | ||||||||
| SBP | 1.03 (1.01–0.15) | <0.05 | 1.04 (1.00–1.08) | <0.05 | 1.01 (1.00–1.03) | 0.11 | ||||
| DBP | 1.03 (1.00–1.07) | <0.05 | 1.05 (0.99–1.11) | 0.11 | 1.02 1.00–1.05) | 0.09 | ||||
| LVMI | 1.01 (1.00–1.02) | 0.06 | 1.01 (1.00–1.03) | <0.05 | ||||||
| IMT | 1.66 (1.29–2.14) | <0.001 | 2.16 (1.48–3.16) | <0.001 | 1.63 (1.10–2.42) | <0.05 | 1.57 (1.15–2.14) | <0.01 | ||
| MACE | 2.02 (1.14–3.56) | <0.05 | 2.81 (1.08–7.30) | <0.05 | 11.26 (3.78–33.51) | <0.001 | ||||
| AR | 1.46 0.86–2.48) | 0.16 | ||||||||
| Graft loss | 1.64 (0.91–2.95) | 0.10 | ||||||||
| CPITN | 2.85 (1.10–7.39) | <0.05 | −0.49 (0.20–1.18) | 0.11 | −0.56 (0.30–1.05) | 0.07 | ||||
DWFG, death with functioning graft; CVD, cardio- or cerebrovascular; MACE, major adverse cardiovascular events; HR, hazard ratio; HLA MM I, human leukocyte antigen class I mismatch; DGF, delayed graft function; CRP, C-reactive protein; Scr, serum creatinine concentration; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVMI, left ventricular mass index; IMT, intima-media thickness; AR, acute rejection; CPITN, Community Periodontal Index of Therapeutic Needs.